Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Teva Pharmaceutical Indus's TEVA short percent of float has risen 16.99% since its last report. The company recently reported ...

Buying $1000 In TEVA: If an investor had bought $1000 of TEVA stock 5 years ago, it would be worth $2,118.31 today based on a ...

As Deckers prepares to unveil its Q3 earnings, can its innovative strategies and brand strength offset the looming margin ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

In terms of the best places for stargazing in Big Bend National Park, all you really need to do is find a spot away from ...

The general public can return any Hoka product within 30 days of purchase. Hoka rewards members (it’s free to sign up) get a ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...